Preliminary Analysis of the Results of Selective Therapy Against Strongyles in Pasturing Horses

Control of horse parasites often omits application of measures to eradicate the free-living stages in pastures and frequently relies on chemotherapy only. Selective therapy was used for Spanish Sport horses grazing either in the same pasture (continuous) or in rotated meadows. In each group, equines exceeding a cutoff value of 300 strongyle eggs per gram of feces received ivermectin or moxidectin. Efficacy of the treatment was assessed by estimating reduction of fecal egg counts and the number of horses shedding parasite eggs (PHR). Coprocultures revealed presence of the cyathostomins Cyathostomum and Gyalocephalus spp. In all treated groups, a 100% value for both reduction of fecal egg counts and PHR against cyathostomins was obtained, and PHR values ranged from 100% to 12%. The longest strongyle egg reappearance period was observed in horses undergoing rotation grazing and receiving ivermectin (9 weeks), compared with a 6-week period recorded for the other treated equines. Our results seem to point that the efficacy of selective therapy in equine herds could be reduced if the horses with fecal egg counts below the threshold value (thus not receiving chemotherapy) remain grazing in the same pastures with the treated ones. It is strongly suggested that interested parties consider performing periodic fecal analyses to monitor fecal egg counts, together with the percentage of horses passing eggs in feces, to improve the effect of this procedure.     

Strongyle egg shedding consistency in horses on farms using selective therapy in Denmark

Knowledge of horses that shed the same number of strongyle eggs over time can lead to the optimization of parasite control strategies. This study evaluated shedding of strongyle eggs in 424 horses on 10 farms when a selective anthelmintic treatment regime was used over a 3-year period. Faecal egg counts were performed twice yearly, and horses exceeding 200 eggs per gram (EPG) of faeces were treated. The results are presented as probabilities of the egg count outcome, when two previous egg counts are known. A horse with no strongyle eggs detected in the two previous faecal examinations had an 82% probability of a zero, and a 91% of being below 200 eggs per gram in the third examination. A horse with the two previous egg counts below 200 EPG had an 84% probability of being below 200 EPG the third time as well. When faecal egg counts exceeded 200 EPG on the previous two counts, the probability for a horse exceeding 200 EPG the third time was 59%. In conclusion, these data demonstrate consistent shedding from one grazing season to another in a majority of horses despite treatment of horses exceeding 200 EPG.     

Cyathostomes in horses in Canada resistant to pyrantel salts and effectively removed by moxidectin

Clinical trials using fecal egg count reduction tests and coproculture were conducted with yearlings and mares on a farm in 1997. Fecal samples were taken from each horse to estimate the number of strongyle eggs/g feces with Cornell-Wisconsin centrifugal flotation and Cornell-McMaster dilution techniques. Eleven of 15 yearlings, which had been on a daily feeding of grain with pyrantel tartrate for 66 d were found with strongyle eggs in feces. This was the first time the in-feed medication had been used on the farm. Nine yearlings were randomised into three groups; continuation of daily pyrantel tartrate or one treatment with pyrantel pamoate or moxidectin. Two of three yearlings given pyrantel tartrate or pamoate had no reduction in the eggs/g feces. These six yearlings were then given moxidectin and in all yearlings the eggs/g feces was reduced to zero. The 66 d of pyrantel tartrate use was an inadequate time for development of resistant cyathostomes and a hypothesis was the resistance was due to extensive use on the farm over many years of pyrantel pamoate at twice the label dose for control of tapeworms. That hypothesis was tested with 12 mares with strongyle eggs in the feces randomised into two treatment groups: pyrantel pamoate at label dose or moxidectin. Five of six mares given pyrantel had <80% reduction in egg/g feces. These mares were then given moxidectin and in all mares the eggs/g feces was reduced to zero. Only cyathostomes were found on culture and apparently there was side resistance among the pyrantel salts.     

Effectiveness of oxibendazole against benzimidazole-resistant strongyles in horses

Twenty-eight horses with a residual burden of strongyle eggs in the faces after treatment with mebendazole (MBZ) paste were treated with a suspension of either MBZ or oxibendazole (OBZ). Fecal samples were collected before and 14 days after these treatments. The number of strongyle eggs/g (epg) of feces for each horse was estimated using the Cornell-McMaster dilution and the Cornell-Wisconsin double centrifugation procedures. The epg for each horse was transformed using log (× + 1) and in an analysis of variance of the reduction in egg count for each horse on the logarithmic scale, there was a highly significant difference between the treatments. The mean epg was increased in the MBZ-treated horses and reduced in the OBZ-treated horses, but the reduction was only by 82% with an upper confidence limit of 89%. Subsequently, the horses were retreated with MBZ and OBZ suspensions without significant reduction in the mean epg for OBZ-treated horses.     

Comparison of ivermectin, oxibendazole, and pyrantel pamoate in suppressing fecal egg output in horses

Thirty resident horses at a boarding stable in Alberta were used to evaluate the relative efficacies of ivermectin, oxibendazole, and pyrantel pamoate in reducing fecal egg output in adult horses under routine management conditions during spring and early summer, and to more clearly define the duration of suppression of fecal egg production following anthelmintic treatment. Horses were blocked according to pretreatment egg counts and randomly assigned to one of three treatments: pyrantel pamoate at 6.6 mg/kg body weight; oxibendazole at 10 mg/kg body weight; or ivermectin at 200 μg/kg body weight. All treatments were administered orally as a paste on day 0.Fecal samples were collected for examination by the modified Wisconsin procedure before treatment, and then at 4-11 day intervals up to day 72.

Very few if any strongyle eggs were found in the feces of any horses up to day 35. On days 42, 50 and 57, the geometric mean egg count for the ivermectin group was significantly (p<0.05) lower than that for the oxibendazole or pyrantel pamoate groups. Based on a survival curve analysis of the data, the mean number of days for recurrence of eggs in the feces was significantly longer for the ivermectin group than for the oxibendazole and pyrantel pamoate groups.

Under conditions encountered in this study, the posttreatment interval to resumption of fecal egg out-put in horses treated with ivermectin was eight to nine weeks, compared with five to six weeks for horses treated with oxibendazole or pyrantel pamoate.

     

Daily Variability of Strongyle Fecal Egg Counts in Horses

Strongyle parasites are ubiquitous in grazing horses and constitute a potential threat to equine health. Feces were collected from six horses four times daily over a period of 5 days. Fecal egg counts (FECs) were performed to identify any diurnal rhythms in strongyle egg shedding and to quantify variability at the different levels: individual horses, repeated counts, repeated subsamples, different time points, and different days. No significant differences in FECs were found between the different time points (P = .11). The variables—horse, day, subsample, and egg count—accounted for a variance of 104.83, 0.10, 7.24, and 5.61, respectively. The apparent lack of additional variability between the four different time points suggests that time of the day chosen for collecting fecal samples does not constitute a source of error in field studies. The majority of variability exists between different subsamples and repeated egg counts on the same subsamples, whereas the variability of FECs between following days can be considered negligible. The findings of this study have implication for designing and performing field surveillance of strongyle FEC levels and applying the FEC reduction test for evaluating anthelmintic efficacy.     

Efficacy studies with three formulations of cambendazole in horses.

Treatment with 3 formulations of cambendazole (paste, pellets, and suspension) was compared with thiabendazole treatment in 181 Quarter Horses (females and intact and altered males) of different ages in 2 experiments. The mean output of strongyle eggs, as measured by eggs per gram of feces (epg), was reduced by at least 95% by the 3 formulations of cambendazole compared with pretreatment epg and epg in simultaneously nonmedicated horses. Eggs of Parascaris equorum were seen in 19 of the younger horses in experiment I. Parascaris eggs were not seen in postmedication fecal samples from 14 horses treated wtih cambendazole. Of the 5 horses treated with thiabendazole, 2 had postmedication Parascaris egg counts.     

Alternative antiparasitic treatment of horses with pyrantel pamoate suspension and ivermectin oral solution compared with horses treated only with ivermectin oral solution

A practical parasite control program was evaluated in a 2-year clinical trial using pyrantel pamoate suspension (PYR) and ivermectin oral solution (IVM) in a seasonal rotation program, in comparison with continued use of IVM given at 2-month intervals. At least 15 horses in each of 2 treatment groups were distributed over 8 locations. In the alternation program, IVM was given twice (October, December) during the botfly (Gasterophilus spp.) season and again in April to treat against the lighter botfly season and to kill existing Onchocerca microfilariae prior to heavy Culicoides swarming. Pyrantel was given in February, June and August to continue suppression of strongyle infections and to treat against potentially developing Anoplocephala infections. In the program of IVM continuous use, the drug was given on the same schedule as either treatment on the alternation program.The course of strongyle infections was monitored by fecal sample analyses (EPG) at semimonthly intervals and by larval cultures of treatment pairs prepared at each treatment interval (alternation program) or at 4-month intervals (continuous IVM program). The strongyle egg count numbers were reduced to zero by the first IVM treatment, increased only slightly by the next treatment at 2 months, and repeated the reduced pattern with each treatment for 2 years. The alternation program in the first year had typical responses to each drug: IVM reducing strongyle EPG counts to zero which increased slightly at 2 months, followed by the PYR treatment, which reduced the strongyle egg counts for 4 weeks with rebound at 6 and 8 weeks. At the end of the first year and into the second, the IVM treatments of October and December established a zero or low strongyle EPG pattern which continued through the spring with PYR and IVM treatments. The second summer PYR treatments then maintained far better cyathostome control than had been reported for this drug. There may be a complementary or enhancing effect by prior treatment with ivermectin within the rotation protocol. The practical therapeutic compatibility between these 2 antiparasitics became obvious. Anoplocephala eggs were found in feces of some horses treated with IVM only, but no Anoplocephala eggs were found in post-treatment feces of horses treated on the alternation program.Strongyle larval cultures prepared as treatment pairs indicated high efficacy by ivermectin throughout the 2 years whether used alone or as a rotational drug, with improved cyathostome control by pyrantel pamoate. The combined use of EPG determinations and concurrent larval cultures in anthelmintic evaluations provide a greater spectrum of reliable results than from parasite egg counts alone.     

Field evaluation of moxidectin/praziquantel oral gel in horses

The safety and efficacy of 2% moxidectin/12.5% praziquantel oral gel administered at a rate of 0.4 mg moxidectin and 2.5 mg praziquantel/kg was studied in client-owned horses under field use conditions. Four hundred horses (300 treated with moxidectin/praziquantel oral gel and 100 treated with vehicle) were enrolled, feces were collected, and eggs were counted. Investigators as well as horse owners were masked to treatment assignment. No adverse reactions to treatment were observed in any horses. Moxidectin/praziquantel gel reduced Anoplocephala spp by more than 99% and provided a significant (P <.05) reduction (> 98%) in the strongyle egg count of treated horses.     

Alternative antiparasitic treatment of horses with pyrantel pamoate suspension and ivermectin oral solution compared with horses treated only with ivermectin

A practical parasite control program was evaluated in a 2-year clinical trial using pyrantel pamoate suspension (PYR) and ivermectin oral solution (IVM) in a seasonal rotation program, in comparison with continued use of IVM given at 2-month intervals. At least 15 horses in each of 2 treatment groups were distributed over 8 locations. In the alternation program, IVM was given twice (October, December) during the botfly (Gasterophilus spp.) season and again in April to treat against the lighter botfly season and to kill existing Onchocerca microfilariae prior to heavy Culicoides swarming. Pyrantel was given in February, June and August to continue suppression of strongyle infections and to treat against potentially developing Anoplocephala infections. In the program of IVM continuous use, the drug was given on the same schedule as either treatment on the alternation program.The course of strongyle infections was monitored by fecal sample analyses (EPG) at semimonthly intervals and by larval cultures of treatment pairs prepared at each treatment interval (alternation program) or at 4-month intervals (continuous IVM program). The strongyle egg count numbers were reduced to zero by the first IVM treatment, increased only slightly by the next treatment at 2 months, and repeated the reduced pattern with each treatment for 2 years. The alternation program in the first year had typical responses to each drug: IVM reducing strongyle EPG counts to zero which increased slightly at 2 months, followed by the PYR treatment, which reduced the strongyle egg counts for 4 weeks with rebound at 6 and 8 weeks. At the end of the first year and into the second, the IVM treatments of October and December established a zero or low strongyle EPG pattern which continued through the spring with PYR and IVM treatments. The second summer PYR treatments then maintained far better cyathostome control than had been reported for this drug. There may be a complementary or enhancing effect by prior treatment with ivermectin within the rotation protocol. The practical therapeutic compatibility between these 2 antiparasitics became obvious. Anoplocephala eggs were found in feces of some horses treated with IVM only, but no Anoplocephala eggs were found in post-treatment feces of horses treated on the alternation program.Strongyle larval cultures prepared as treatment pairs indicated high efficacy by ivermectin throughout the 2 years whether used alone or as a rotational drug, with improved cyathostome control by pyrantel pamoate. The combined use of EPG determinations and concurrent larval cultures in anthelmintic evaluations provide a greater spectrum of reliable results than from parasite egg counts alone.     

Anti-strongyle activity of a propylene glycol-glycerol formal formulation of ivermectin in horses (mares)

Four groups of 10 horses (mares) each were treated with a 1% solution of ivermectin (200 micrograms/kg of body weight) in a propylene glycol-glycerol formal base orally, a 1% solution of ivermectin (200 micrograms/kg) in a propylene glycol-glycerol formal base via nasogastric tube, a 1.87% paste of ivermectin (200 micrograms/kg) orally, or a 22.7% paste of oxibendazole (10 mg/kg) orally. Fecal examinations were done before treatment and on posttreatment days (PTD) 14, 28, 42, 56, and 70. Strongyle egg per gram counts and sugar flotation fecal examinations were performed. Results of fecal examinations before treatment were similar in all horses. All horses treated with ivermectin had similar percentages of reductions in mean strongyle egg per gram counts after treatment; 100% on PTD 14, 28, and 56 and 93.4% to 98.7% on PTD 70. All ivermectin treatment groups had 0 horses detected as passing strongyle eggs on PTD 14 and 28, 0 to 2 on PTD 42, 3 to 5 on PTD 56, and 8 to 9 on PTD 70. Horses treated with oxibendazole had 99.9%, 99.7%, 92.9% 78.6%, and 54.5% reductions in mean strongyle egg per gram counts and 5, 7, 8, 9, and 9 horses detected as passing strongyle eggs on PTD 14, 28, 42, 56, and 70, respectively. Adverse reactions to treatment were not observed.     

Equine helminth infections: control by selective chemotherapy

A programme of selective anthelmintic therapy was used in a herd of 31 horses. Faecal egg counts were done during the months of September, November, January, March, May and the following September. Horses with greater than or equal to 100 eggs per gram (epg) were treated with ivermectin, and those with less than 100 epg were not treated. The criteria for adequate internal parasite control in the herd was a median herd faecal egg count of less than or equal to 100 epg. Effectiveness of selective therapy was assessed by faecal egg count after nine months of treatment and was determined to be adequate when a median herd egg count of 0 epg was obtained. However, on returning from pasture the following September, median herd egg count had risen to 325 epg. A statistically significant correlation was seen in the paired September faecal egg counts of the horses in that initial September faecal egg count was predictive for the following September. Initial September faecal egg count was related to the number of anthelmintic treatments required during the period of selective therapy, whereas age of horse was not. We propose that faecal egg counts be incorporated into strategic anthelmintic programmes as an economical tool for identifying and targeting herd members predisposed to shedding elevated numbers of helminth eggs.     

Control of endoparasites in horses with a gel containing moxidectin and praziquantel

A gel formulation containing moxidectin (20 g/kg) and praziquantel (125 g/kg) reduced the geometric mean faecal strongyle egg count in horses to below 100 eggs per gram of faeces (epg) for at least 12 weeks despite their being exposed continuously to reinfection from pasture grazed by treated and untreated horses. The geometric mean egg count of horses treated with a proprietary paste containing abamectin (3.7 g/kg) and praziquantel (46.2 g/kg) increased steadily from six weeks after the treatment, peaking at over 820 epg after 12 weeks. Relative to the efficacy of the abamectin/praziquantel treatment, the reduction in mean faecal egg count compared with the pretreatment counts was significantly (P<0.05) better in the horses treated with moxidectin and praziquantel from eight weeks after the treatment. Both products eliminated tapeworms from horses in a non-invasive modified critical trial.     

Evidence of Ivermectin Resistance by Parascaris equorum on a Texas Horse Farm

By collecting fecal samples every 2 weeks beginning at 2 months of age, 32 foals from a single Texas farm were monitored. The foals were administered ivermectin paste at the time of the first collection and again monthly. When foals had Parascaris egg counts higher 2 weeks after ivermectin treatment than at treatment, they were administered pyrantel pamoate at the manufacturer's recommended dose (6.6 mg/kg) or at twice the recommended dose (13.2 mg/ kg) when tapeworm eggs were also detected. An elevation or only minimal reduction (less than 75%) in Parascaris egg counts was seen 2 weeks after ivermectin treatment until the foals were 8 months of age, at which time there was an 85% reduction in fecal egg count after treatment. When pyrantel was administered at the manufacturer's recommended dose, a 42% to 84% reduction in egg counts occurred, but at 13.2 mg/kg there was a 98% to 100% reduction in fecal egg counts 2 weeks posttreatment. However, pyrantel failed to control strongylate egg counts even at the elevated dose, whereas ivermectin reduced strongylate fecal egg counts by greater than 99%, determined 2 weeks posttreatment. Pyrantel, but not ivermectin, lowered Parascaris egg counts. Ivermectin, but not pyrantel, lowered strongyle egg counts 2 weeks post administration. A single drug for all ages of horses approach to parasite control requires rethinking. Combinations of drugs or more careful evaluation of anthelmintics in foals may be necessary for continued parasite control.     

Fecal shedding of Salmonella spp by horses in the United States during 1998 and 1999 and detection of Salmonella spp in grain and concentrate sources on equine operations

OBJECTIVE: To estimate prevalence of fecal shedding of Salmonella spp among horses in the US horse population and prevalence of Salmonella spp in grain or other concentrate used as horse feed on equine operations in the United States. DESIGN: Cross-sectional survey. SAMPLE POPULATION: Horses on 972 operations in 28 states. PROCEDURE: Fecal samples were collected from horses resident at each operation. Only a single sample was collected from any individual horse; number of horses from which samples were collected on each operation was determined on the basis of number of horses on the operation. A single sample of grain or concentrate was also collected from each operation. All samples were tested for Salmonella spp by means of bacterial culture. RESULTS: Overall, 0.8% (SE, 0.5) of resident horses shed Salmonella spp in their feces. The overall prevalence of operations positive for fecal shedding of Salmonella spp (i.e., operations with > or = 1 horse shedding Salmonella spp in its feces) was 1.8% (SE, 0.7). Prevalence of grain or other concentrate samples positive for Salmonella spp was 0.4%. Serotypes of Salmonella spp that were identified in grain or other concentrate were not those typically associated with clinical disease in horses. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that the national prevalence of fecal shedding of Salmonella spp by horses in the United States was 0.8%, and that prevalence of Salmonella spp in grain or other concentrate used for horse feed was 0.4%.     

Pyrantel pamoate resistance in horses receiving daily administration of pyrantel tartrate

CASE DESCRIPTIONS: 16 horses treated daily with pyrantel tartrate (2.64 mg/kg [1.2 mg/lb], PO) as part of a prophylactic anthelmintic program. CLINICAL FINDINGS: Fecal worm egg counts (FWECs) were obtained on all 16 horses. Mean FWEC was 478 eggs/g (epg; range, 0 to 4,075 epg). Three of the 16 horses were responsible for 85% of the total fecal egg output for the herd on the day of sampling. Six horses had FWECs < 200 epg. Three horses that had arrived within 4 months of the sampling date had FWECs < 100 epg. TREATMENT AND OUTCOME: An FWEC reduction test was initiated the day after FWECs were obtained; all horses with FWECs > 100 epg (9 horses) were treated with pyrantel pamoate (6.6 mg/kg [3 mg/lb], PO), and 14 days later, the FWEC was repeated. During the 14-day period, all horses received pyrantel tartrate (2.64 mg/kg, PO) daily. Fecal worm egg count reduction was calculated for each horse. Mean FWEC reduction for the group was 28.5% (range, increase of 21% in FWECs 14 days after treatment to a decrease of 100% in FWEC 14 days after treatment). CLINICAL RELEVANCE: Farms should be monitored for cyathostomes resistant to pyrantel pamoate prior to use of pyrantel tartrate. Fecal worm egg counts should be monitored routinely in horses before and after treatment to ensure efficacy of cyathostome control measures.     

Strongylus vulgaris associated with usage of selective therapy on Danish horse farms-Is it reemerging?

Nematodes belonging to the order Strongylida are ubiquitous in grazing horses, and the large strongyle Strongylus vulgaris is considered the most pathogenic. This parasite was originally described widely prevalent in equine establishments, but decades of frequent anthelmintic treatment appears to have reduced the prevalence dramatically. Increasing levels of anthelmintic resistance in cyathostomin parasites have led to implementation of selective therapy to reduce further development of resistance. It has been hypothesized that S. vulgaris could reoccur under these less intensive treatment circumstances. The aim with the present study was to evaluate the occurrence of S. vulgaris and the possible association with usage of selective therapy. A total of 42 horse farms in Denmark were evaluated for the presence of S. vulgaris using individual larval cultures. Farms were either using a selective therapy principle based on regular fecal egg counts from all horses, or they treated strategically without using fecal egg counts. A total of 662 horses were included in the study. Covariate information at the farm and horse level was collected using a questionnaire. The overall prevalence of S. vulgaris was 12.2% at the individual level and 64.3% at the farm level. Farms using selective therapy had horse and farm prevalences of 15.4% and 83.3%, respectively, while the corresponding results for farms not using selective therapy were 7.7% and 38.9%. These findings were found statistically significant at both the horse and the farm level. Stud farms using selective therapy were especially at risk, and occurrence of S. vulgaris was significantly associated with the most recent deworming occurring more than six months prior. The results suggest that a strict interpretation of the selective therapy regimen can be associated with an increased prevalence of S. vulgaris. This suggests that modifications of the parasite control programs could be considered on the studied farms, but it remains unknown to which extent this can be associated with increased health risks for infected horses.     

The persistence of benzimidazole-resistant cyathostomes on horse farms in Ontario over 10 years and the effectiveness of ivermectin and moxidectin against these resistant strains

Three clinical trials with fecal egg count reduction tests and coproculture were conducted on 2 standardbred farms in Ontario. On Farm A, the treatment groups were mebendazole and ivermectin in trial 1, and fenbendazole and moxidectin in another. On Farm B, treatment groups were mebendazole and ivermectin. All horses treated with mebendazole or fenbendazole were subsequently treated with ivermectin or moxidectin. Strongyle eggs/g feces were estimated pre- and post-treatment using the Cornell-McMaster dilution and Cornell-Wisconsin centrifugal flotation techniques. After treatment, there was no change in the arithmetic mean eggs/g feces for horses given mebendazole, and a reduction of only 49.1% for those given fenbendazole. All horses receiving ivermectin or moxidectin had their egg counts reduced to 0. Only cyathostomes were found on culture. On both farms the benzimidazole resistant strains appeared to have persisted for at least 10 years. Development of and monitoring for anthelmintic resistance are briefly discussed.     

An Investigation of Variables in a Fecal Flotation Technique

Several variables in a standard vial fecal gravitational flotation technique were investigated. These were the specific gravity of the sodium nitrate flotation solution, duration of flotation and mesh sizes of strainers. The number of eggs which floated and adhered to a coverslip were counted and estimates of the number of eggs remaining in the strained fecal suspension and in the feces trapped on the strainer were made. Eggs from hookworms, Trichuris vulpis and Toxocara canis in feces from dogs, Nematodirus spp. from sheep and Parascaris equorum from horses floated equally well in solutions with specific gravities (SpGr) ranging from 1.22-1.38. Taenia spp. from dogs had a slightly narrower range (SpGr 1.27-1.38) for best recovery. Eggs from Haemonchus contortus from sheep appeared to float best between SpGr 1.22- 1.32. Strongyles from one horse floated best with SpGr 1.27-1.32 and from another with SpGr 1.11-1.38. Coccidial oocysts from sheep floated best in a narrow range of SpGr from 1.22-1.27. However, as the SpGr of the solution was increased the recognition of eggs under the coverslip was increasingly difficult and especially so at SpGr 1.38 with sheep feces. This was due to the increasing amount of debris and the more rapid formation of crystals with evaporation with solutions of higher SpGr. It appeared, therefore, that solutions with SpGr of 1.22-1.35 would be best for routine laboratory use. At specific gravity 1.27, there appeared to be no difference in the number of eggs recovered for a four, eight and 12 min flotation period.

Only 3-7% of the eggs in 4 g of feces were counted under the coverslip. This poor efficacy resulted first because approximately 50% of the eggs were trapped in the feces and retained on the strainer. Secondly, only one half of the strained fecal suspension, containing approximately 25% of the eggs, was placed in the vial for examination. Thirdly, of those eggs in the vial only 16-29% were counted under the coverslip. When the second half of the strained fecal suspension was placed in another vial, the amount of debris and air bubbles adhering to the coverslip was much less than that for the first vial. Egg counts for both vials appeared similar and it may be that when debris is excessive the fecal examination should involve counts from a second vial. The use of strainers finer than the standard tea strainer and the addition of minimal amounts of detergent did not increase the egg count.

     

Evaluation of febantel used concurrently with piperazine citrate in horses

Fifty horses from a herd known to have benzimidazole-resistant small strongyles were treated with febantel (6 mg/kg), combinations of febantel (6 mg/kg) and piperazine citrate (25 or 55 mg base/kg), thiabendazole (44 mg/kg), or placebo (0.6 ml of water/kg). Pretreatment and 7-day posttreatment fecal examinations were done. Fecal cultures, strongyle egg per gram (epg) counts, sugar flotation fecal examinations, and in vitro testing for benzimidazole resistance were performed. Results of fecal examinations before treatment were similar in all horses, and results of testing were positive for benzimidazole resistance. Horses treated with febantel and piperazine at all dosages had significantly lower mean strongyle epg counts and greater percentage reduction in mean strongyle epg counts (99.7% to 99.9%) 7 days after treatment, compared with those determined for horses treated with febantel, thiabendazole, or placebo. Adverse reactions to treatment were not observed.